# The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

> **NCT01220570** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 63 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ridaforolimus + Dalotuzumab
- **DRUG:** Ridaforolimus
- **DRUG:** Dalotuzumab

## Key facts

- **NCT ID:** NCT01220570
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220570, "The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01220570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*